D the bronchoscopy technique for lung function and helped to draft

Author specifics 1 Faculty of Veterinary and Agricultural Biotin-VAD-FMK manufacturer Science, The University of Melbourne, Cyclosporine chemical information Parkville, VIC, Australia. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a valuable tool to investigate remedy title= jir.2011.0103 selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the end from the animal experiments. None with the authors had distinct funding for this study. C. Samuel is supported by a National Well being Healthcare Investigation Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Chrishan Samuel is supported by a National Overall health Healthcare Study Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Author particulars 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page title= fnhum.2014.00074 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al.